ABBOTT LABORATORIES Cost of Revenue
ABBOTT LABORATORIES (ABT) reported Cost of Revenue of $4.89 billion for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-04-29
- ABBOTT LABORATORIES cost of goods and services sold for the quarter ending 2026-03-31 was $4.89B, a 9.44% increase year-over-year.
- ABBOTT LABORATORIES cost of goods and services sold for the quarter ending 2025-12-31 was $4.92B, a 0.40% decline year-over-year.
- ABBOTT LABORATORIES cost of goods and services sold for the quarter ending 2025-09-30 was $5.08B, a 8.02% increase year-over-year.
- ABBOTT LABORATORIES cost of goods and services sold for the quarter ending 2025-06-30 was $4.85B, a 5.45% increase year-over-year.
- ABBOTT LABORATORIES cost of goods and services sold for fiscal 2025 was $19.32B, a 3.28% increase from fiscal 2024.
- ABBOTT LABORATORIES cost of goods and services sold for fiscal 2024 was $18.71B, a 4.07% increase from fiscal 2023.
- ABBOTT LABORATORIES cost of goods and services sold for fiscal 2023 was $17.98B, a 6.10% decline from fiscal 2022.
- ABBOTT LABORATORIES cost of goods and services sold for fiscal 2022 was $19.14B, a 3.26% increase from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-03-31 | $4.89B 10-Q · filed 2026-04-29 | $9.81B derived: sum of 2 quarters · filed 2026-04-29 | $14.89B derived: sum of 3 quarters · filed 2026-04-29 | $19.74B derived: sum of 4 quarters · filed 2026-04-29 |
| 2025-12-31 | $4.92B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $10.00B derived: sum of 2 quarters · filed 2026-02-20 | $14.85B derived: sum of 3 quarters · filed 2026-02-20 | $19.32B 10-K · filed 2026-02-20 |
| 2025-09-30 | $5.08B 10-Q · filed 2025-10-29 | $9.93B derived: sum of 2 quarters · filed 2025-10-29 | $14.40B 10-Q · filed 2025-10-29 | $19.34B derived: sum of 4 quarters · filed 2026-04-29 |
| 2025-06-30 | $4.85B 10-Q · filed 2025-07-30 | $9.32B 10-Q · filed 2025-07-30 | $14.26B derived: sum of 3 quarters · filed 2026-04-29 | $18.96B derived: sum of 4 quarters · filed 2026-04-29 |
| 2025-03-31 | $4.47B 10-Q · filed 2026-04-29 | $9.41B derived: sum of 2 quarters · filed 2026-04-29 | $14.11B derived: sum of 3 quarters · filed 2026-04-29 | $18.71B derived: sum of 4 quarters · filed 2026-04-29 |
| 2024-12-31 | $4.94B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $9.64B derived: sum of 2 quarters · filed 2026-02-20 | $14.24B derived: sum of 3 quarters · filed 2026-02-20 | $18.71B 10-K · filed 2026-02-20 |
| 2024-09-30 | $4.70B 10-Q · filed 2025-10-29 | $9.30B derived: sum of 2 quarters · filed 2025-10-29 | $13.76B 10-Q · filed 2025-10-29 | $18.32B derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-06-30 | $4.60B 10-Q · filed 2025-07-30 | $9.07B 10-Q · filed 2025-07-30 | $13.62B derived: sum of 3 quarters · filed 2026-02-20 | $18.23B derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-03-31 | $4.46B 10-Q · filed 2025-04-30 | $9.02B derived: sum of 2 quarters · filed 2026-02-20 | $13.62B derived: sum of 3 quarters · filed 2026-02-20 | $18.11B derived: sum of 4 quarters · filed 2026-02-20 |
| 2023-12-31 | $4.56B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $9.16B derived: sum of 2 quarters · filed 2026-02-20 | $13.64B derived: sum of 3 quarters · filed 2026-02-20 | $17.98B 10-K · filed 2026-02-20 |
| 2023-09-30 | $4.61B 10-Q · filed 2024-10-31 | $9.09B derived: sum of 2 quarters · filed 2024-10-31 | $13.42B 10-Q · filed 2024-10-31 | $18.01B derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-06-30 | $4.48B 10-Q · filed 2024-07-31 | $8.81B 10-Q · filed 2024-07-31 | $13.41B derived: sum of 3 quarters · filed 2025-02-21 | $18.04B derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-03-31 | $4.33B 10-Q · filed 2024-05-02 | $8.92B derived: sum of 2 quarters · filed 2025-02-21 | $13.55B derived: sum of 3 quarters · filed 2025-02-21 | $18.49B derived: sum of 4 quarters · filed 2025-02-21 |
| 2022-12-31 | $4.59B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $9.22B derived: sum of 2 quarters · filed 2025-02-21 | $14.15B derived: sum of 3 quarters · filed 2025-02-21 | $19.14B 10-K · filed 2025-02-21 |
| 2022-09-30 | $4.63B 10-Q · filed 2023-11-01 | $9.56B derived: sum of 2 quarters · filed 2023-11-01 | $14.55B 10-Q · filed 2023-11-01 | $19.32B derived: sum of 4 quarters · filed 2024-02-16 |
| 2022-06-30 | $4.93B 10-Q · filed 2023-08-03 | $9.92B 10-Q · filed 2023-08-03 | $14.69B derived: sum of 3 quarters · filed 2024-02-16 | $19.11B derived: sum of 4 quarters · filed 2024-02-16 |
| 2022-03-31 | $4.99B 10-Q · filed 2023-05-04 | $9.75B derived: sum of 2 quarters · filed 2024-02-16 | $14.18B derived: sum of 3 quarters · filed 2024-02-16 | $19.12B derived: sum of 4 quarters · filed 2024-02-16 |
| 2021-12-31 | $4.77B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-16 | $9.19B derived: sum of 2 quarters · filed 2024-02-16 | $14.14B derived: sum of 3 quarters · filed 2024-02-16 | $18.54B 10-K · filed 2024-02-16 |
| 2021-09-30 | $4.42B 10-Q · filed 2022-11-01 | $9.37B derived: sum of 2 quarters · filed 2022-11-01 | $13.77B 10-Q · filed 2022-11-01 | $18.26B derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-06-30 | $4.95B 10-Q · filed 2022-08-02 | $9.35B 10-Q · filed 2022-08-02 | $13.84B derived: sum of 3 quarters · filed 2023-02-17 | $17.81B derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-03-31 | $4.40B 10-Q · filed 2022-05-03 | $8.89B derived: sum of 2 quarters · filed 2023-02-17 | $12.86B derived: sum of 3 quarters · filed 2023-02-17 | $16.12B derived: sum of 4 quarters · filed 2023-02-17 |
| 2020-12-31 | $4.49B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $8.46B derived: sum of 2 quarters · filed 2023-02-17 | $11.72B derived: sum of 3 quarters · filed 2023-02-17 | $15.00B 10-K · filed 2023-02-17 |
| 2020-09-30 | $3.97B 10-Q · filed 2021-11-03 | $7.23B derived: sum of 2 quarters · filed 2021-11-03 | $10.51B 10-Q · filed 2021-11-03 | $13.94B derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-06-30 | $3.26B 10-Q · filed 2021-08-04 | $6.54B 10-Q · filed 2021-08-04 | $9.98B derived: sum of 3 quarters · filed 2022-02-18 | $13.34B derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-03-31 | $3.28B 10-Q · filed 2021-05-05 | $6.71B derived: sum of 2 quarters · filed 2022-02-18 | $10.07B derived: sum of 3 quarters · filed 2022-02-18 | $13.35B derived: sum of 4 quarters · filed 2022-02-18 |
| 2019-12-31 | $3.43B derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $6.79B derived: sum of 2 quarters · filed 2022-02-18 | $10.07B derived: sum of 3 quarters · filed 2022-02-18 | $13.23B 10-K · filed 2022-02-18 |
| 2019-09-30 | $3.36B 10-Q · filed 2020-11-04 | $6.64B derived: sum of 2 quarters · filed 2020-11-04 | $9.80B 10-Q · filed 2020-11-04 | $12.99B derived: sum of 4 quarters · filed 2021-02-19 |
| 2019-06-30 | $3.28B 10-Q · filed 2020-07-29 | $6.44B 10-Q · filed 2020-07-29 | $9.63B derived: sum of 3 quarters · filed 2021-02-19 | $12.80B derived: sum of 4 quarters · filed 2021-02-19 |
| 2019-03-31 | $3.16B 10-Q · filed 2020-04-29 | $6.35B derived: sum of 2 quarters · filed 2021-02-19 | $9.52B derived: sum of 3 quarters · filed 2021-02-19 | $12.80B derived: sum of 4 quarters · filed 2021-02-19 |
| 2018-12-31 | $3.19B derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-19 | $6.36B derived: sum of 2 quarters · filed 2021-02-19 | $9.64B derived: sum of 3 quarters · filed 2021-02-19 | $12.71B 10-K · filed 2021-02-19 |
| 2018-09-30 | $3.17B 10-Q · filed 2019-10-31 | $6.45B derived: sum of 2 quarters · filed 2019-10-31 | $9.52B 10-Q · filed 2019-10-31 | $12.80B derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-06-30 | $3.28B 10-Q · filed 2019-07-31 | $6.35B 10-Q · filed 2019-07-31 | $9.63B derived: sum of 3 quarters · filed 2020-02-21 | $12.51B derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-03-31 | $3.07B 10-Q · filed 2019-05-01 | $6.35B derived: sum of 2 quarters · filed 2020-02-21 | $9.22B derived: sum of 3 quarters · filed 2020-02-21 | $12.41B derived: sum of 4 quarters · filed 2020-02-21 |
| 2017-12-31 | $3.28B derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $6.16B derived: sum of 2 quarters · filed 2020-02-21 | $9.35B derived: sum of 3 quarters · filed 2020-02-21 | $12.41B 10-K · filed 2020-02-21 |
| 2017-09-30 | $2.88B 10-Q · filed 2018-10-31 | $6.07B derived: sum of 2 quarters · filed 2018-10-31 | $9.13B 10-Q · filed 2018-10-31 | |
| 2017-06-30 | $3.19B 10-Q · filed 2018-08-01 | $6.25B 10-Q · filed 2018-08-01 | ||
| 2016-12-31 | $9.09B 10-K · filed 2019-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |